Panel Discussion: Defining Cross-Indication Expansion Strategies to Maximize the Clinical & Commercial Potential of Antifibrotic Therapies
2:30 pm - Wednesday 2nd December 2026
- Determining when preclinical evidence is sufficiently robust to justify expanding an antifibrotic program into additional fibrotic indications rather than remaining disease-specific
- Identifying the biological, translational, regulatory, and commercial factors that should guide indication prioritization, including shared mechanisms, biomarker availability, clinical endpoints, and unmet need
- Exploring whether future antifibrotic programs should be intentionally designed as multi-indication assets from discovery or whether expansion should remain a staged, indication-by-indication strategy
